HSC Exam Practice

Sample response. Selective toxicity is the ability of a drug to damage or kill a pathogen while causing minimal harm to the host's cells, because the drug's target structure or process is absent or structurally different in the host. It is essential in an antibiotic because a drug that killed host cells along with bacteria would be clinically unusable — the therapeutic goal requires eliminating the pathogen without significant collateral damage to the patient.

Marking notes. 1 mark for the definition: drug targets pathogen structure/process that is absent or different in host cells (must reference the host–pathogen distinction). 1 mark for explaining why it is essential: must state that without selective toxicity the drug would harm the patient as much as the pathogen, making it clinically useless.

Sample response. Bactericidal antibiotics (e.g. penicillins, fluoroquinolones) directly kill bacteria. Bacteriostatic antibiotics (e.g. tetracyclines, macrolides) inhibit bacterial growth and reproduction without directly killing them, relying on the patient's immune system to clear the remaining bacteria. A bactericidal agent is strongly preferred in immunocompromised patients (e.g. those undergoing chemotherapy, transplant recipients, HIV patients with low CD4 counts) because these patients cannot rely on their immune system to eliminate the bacteriostasised bacteria once the antibiotic stops — a bacteriostatic drug would leave viable bacteria that could repopulate and cause renewed infection.

Marking notes. 1 mark for bactericidal (directly kills bacteria, example). 1 mark for bacteriostatic (inhibits growth/reproduction, relies on immune system, example). 1 mark for a correct clinical preference situation: immunocompromised patients — must include a reason (immune system cannot eliminate remaining bacteria after bacteriostatic drug stops).

Sample response. Bacterial ribosomes are 70S (made of 30S and 50S subunits), while human ribosomes are 80S (made of 40S and 60S subunits). The antibiotics that target bacterial ribosomes (e.g. tetracyclines target 30S; macrolides target 50S) bind specifically to the bacterial ribosome's structure; they bind with much lower affinity to the 80S human ribosome because the binding site is structurally different. This difference in ribosome structure is what gives these drugs their selective toxicity.

Marking notes. 1 mark for identifying the structural difference (bacterial 70S vs human 80S). 1 mark for explaining that lower binding affinity to the 80S ribosome reduces harm to human cells. A response that simply says "human cells have different ribosomes" without explaining the binding affinity consequence scores 1/2.

Sample response. Bacteria are free-living cells with their own structures (cell wall, 70S ribosomes, metabolic pathways) that are absent in human cells — these provide multiple distinct, safe targets for antibiotics. Viruses are not cells and do not replicate independently: they use the host cell's own machinery (80S ribosomes, host DNA polymerases, host metabolic pathways) to replicate. This means viruses have very few processes or structures that are genuinely unique to the virus and not shared with the host — making selective targeting without harming host cells much harder. Antiviral drugs must identify the small number of virus-specific enzymes (e.g. viral reverse transcriptase in HIV, viral neuraminidase in influenza) as their targets, but these are fewer and sometimes more variable than bacterial targets, limiting the available drug families and making it harder to achieve good selectivity.

Marking notes. 1 mark for identifying that bacteria are cells with unique structures absent in humans, providing many antibiotic targets. 1 mark for explaining that viruses use host cell machinery for replication, leaving few virus-specific targets. 1 mark for explaining that the small number of unique viral enzymes (with named examples) limits antiviral drug design options and makes selective toxicity harder to achieve.

Sample response. Mechanism 1 — enzymatic inactivation: bacteria produce enzymes that chemically destroy the antibiotic before it can reach its target. Example: beta-lactamase enzymes produced by penicillin-resistant Staphylococcus cleave the beta-lactam ring of penicillins, rendering them inactive. Mechanism 2 — target modification: the antibiotic's binding site on the bacterial target is altered by mutation so the drug can no longer bind effectively. Example: MRSA (methicillin-resistant Staphylococcus aureus) carries the mecA gene encoding an altered penicillin-binding protein (PBP2a) that penicillins cannot bind to, so methicillin cannot inhibit cell wall synthesis in MRSA even at therapeutic concentrations. [Other acceptable mechanisms: efflux pumps (e.g. tetracycline resistance in gram-negative bacteria), reduced membrane permeability via porin loss (e.g. carbapenem resistance in Pseudomonas aeruginosa), metabolic bypass (e.g. trimethoprim resistance).]

Marking notes. 2 marks per mechanism: 1 mark for the correct description of the mechanism; 1 mark for a correct named example from the lesson. Maximum 4 marks for two correctly described mechanisms with two named examples. A mechanism described without a named example, or a name without a correct mechanism, scores 1/2 per item.

Sample response. When symptoms resolve, the antibiotic has substantially reduced the total bacterial population — but not to zero. The bacteria that have survived longest under antibiotic treatment are, on average, the most resistant members of the original population, because susceptible bacteria were eliminated earlier and the most resistant ones persisted longest. Stopping the course at this point removes the selection pressure while a residual population that is enriched for resistance genes is still present. These resistant survivors then reproduce freely via binary fission, passing the resistance gene to all offspring. The bacterial population rebounds, but is now dominated by resistant individuals rather than the susceptible majority that was present at the start of treatment. The prescribed course length is calibrated to reduce the population to zero (or near enough for the immune system to clear) — cutting it short allows the most resistant survivors to repopulate.

Marking notes. 1 mark for identifying that stopping early leaves the most resistant survivors alive (because susceptible bacteria die first, leaving a resistance-enriched residual population). 1 mark for explaining that removing selection pressure allows the survivors to reproduce freely, passing resistance genes to offspring. 1 mark for explicitly linking this to the result: the population rebounds but is now resistance-enriched, making the same antibiotic less effective and potentially requiring a stronger agent.

Sample response (a). In the no-treatment condition, viral load peaks at approximately 100 units on day 4, with the infection persisting above the symptom threshold until approximately day 7–8. In the early-oseltamivir (within 48 h) condition, peak viral load is approximately 45 units, occurring on day 3, and the viral load drops below the symptom threshold by approximately day 5–6, with infection resolved by day 7. Early oseltamivir therefore reduces the peak viral load by approximately 55% compared to no treatment, and shortens the symptomatic period by approximately 2 days.

Marking notes (a). 1 mark for correctly comparing peak viral loads with quoted figures (no treatment ~100 units, early treatment ~45 units). 1 mark for correctly comparing duration: no treatment infection lasts longer, early treatment resolves sooner — must quote approximate days from the graph.

Sample response (b). Neuraminidase is the enzyme influenza uses to cleave sialic acid residues that tether newly assembled virions to the surface of infected host cells. Without neuraminidase activity, new viral particles cannot be released from infected cells and cannot spread to infect adjacent uninfected cells. Oseltamivir inhibits neuraminidase. When started within 48 hours of symptom onset, oseltamivir acts before the peak of viral replication — it prevents the large wave of new virions from escaping infected cells before they have spread broadly through the respiratory epithelium, capping the total viral population that can build up. Starting at 72 hours means three days of uninhibited viral replication and spread have already occurred; neuraminidase inhibition begins after the bulk of viral amplification is already underway, so the peak viral load is higher and the decline is slower than in the early-treatment condition, though still lower than no treatment.

Marking notes (b). 1 mark for correctly explaining the mechanism of neuraminidase inhibitors (blocks virion release from infected cells → prevents spread to new cells). 1 mark for explaining why starting earlier results in lower peak viral load (drug is active before peak replication — caps the amplification phase before it reaches its full extent). 1 mark for explaining why starting at 72 h is less effective (replication has already reached a higher level before inhibition begins — drug still works but cannot cap the already-distributed infection as effectively).

Sample response (c). The biological process responsible for clearing residual virus is the adaptive immune response — specifically, cytotoxic T lymphocytes (CD8+ T cells) killing infected cells and neutralising antibodies from B cells/plasma cells binding to and inactivating extracellular viral particles. Antivirals alone are rarely sufficient to eliminate a viral infection because they only inhibit a specific step in the replication cycle — they do not destroy existing viral particles or clear infected cells. The immune system is required to recognise and eliminate infected cells and inactivate remaining virus. This is why antivirals are most effective early (reducing viral burden so the immune system is not overwhelmed) rather than as a sole treatment capable of eliminating the infection without immune help.

Marking notes (c). 1 mark for identifying the adaptive immune response (accept cytotoxic T cells / neutralising antibodies / immune clearance) as responsible for clearing residual virus. 1 mark for explaining why antivirals alone are insufficient — they inhibit replication but do not destroy existing particles or infected cells; immune clearance is required for complete elimination.

Sample response. The claim that antibiotic resistance is inevitable and therefore cannot be meaningfully slowed is partially defensible as a statement about evolutionary inevitability but substantially wrong as a policy conclusion. The distinction between "unstoppable" and "can be slowed" is critical — resistance will eventually emerge to any antibiotic used at scale, but the rate at which it emerges is profoundly influenced by human behaviour. Slowing that rate is not merely possible: it is the difference between effective antibiotics lasting decades and effective antibiotics lasting years.

The evolutionary mechanism of resistance development is well established. Bacterial populations contain rare variants carrying pre-existing resistance mutations — arising from the high frequency of bacterial replication errors and the absence of DNA proofreading in many bacterial species. When an antibiotic is introduced, it acts as a selection pressure: susceptible bacteria are killed, resistant variants survive and reproduce, and over successive generations the resistant phenotype dominates — natural selection at the population level. This process is real and cannot be stopped entirely while antibiotics are used. Beta-lactamase production in Staphylococcus, MRSA's altered PBP2a, efflux pumps in gram-negative bacteria — these are examples of molecular mechanisms that have already emerged through natural selection and will continue to emerge. Horizontal gene transfer via plasmids accelerates this further by moving resistance genes between species in hours.

However, the rate and speed of resistance emergence is directly determined by the level of selection pressure applied, and this is highly controllable by human behaviour. Three behaviours are critical. First, overprescribing — approximately 30% of antibiotic prescriptions in Australian primary care are inappropriate, typically for viral infections where antibiotics cannot act. Each unnecessary prescription applies selection pressure to bacteria in the patient's microbiome with no therapeutic benefit. Second, stopping courses early — patients who stop antibiotics when symptoms resolve leave a resistance-enriched bacterial survivor population (the most resistant bacteria persist longest) free to repopulate. Third, agricultural use — sub-therapeutic antibiotic concentrations as growth promoters in livestock apply selection pressure across millions of animals simultaneously, and constitute one of the largest global drivers of resistance gene pools outside clinical settings. All three are human behaviours, all three apply selection pressure, and all three can be substantially modified.

Two management strategies warrant critical assessment. Antibiotic stewardship programs — guidelines and enforcement mechanisms that restrict prescribing to indicated infections, reserve last-resort drugs (e.g. vancomycin preserved as a last line in the Australian data where resistance remained near 0% for decades), and promote narrow-spectrum over broad-spectrum agents — directly reduce selection pressure at the population level. The effectiveness evidence includes the MRSA decline from 42% to 28% in Australian hospitals between 2005 and 2020, at least partly attributable to stewardship programs. The limitations are real: stewardship requires sustained compliance, individual GPs face patient pressure to prescribe, and international coordination is poor — resistant bacteria do not respect national borders. Completing antibiotic courses eliminates the most dangerous subset of the clinical exposure (the resistant survivor repopulation) and is potentially modifiable with education. Its limitation is that behaviour change is slow, complex, and compliance is highly variable even in well-informed populations. More structural solutions — agricultural reform to ban growth-promoter antibiotic use, and commercial incentives (e.g. government-backed "push and pull" funding mechanisms for new antibiotic development) — address drivers that individual prescribing behaviour cannot.

The evaluative conclusion is that the claim conflates "inevitable in the long run" with "unable to be slowed" — and this conflation matters for public health. Resistance is evolutionarily inevitable if antibiotics are used at scale, but the speed of emergence and the rate of spread are profoundly human-determined. The evidence that stewardship slows MRSA, and that resistance to vancomycin took decades to appear precisely because it was used restrictively, demonstrates that human policy choices can extend the useful life of antibiotics by years or decades — which translates directly into lives saved. The claim is therefore wrong as a policy conclusion: resistance is not meaningless to resist, even if it cannot be permanently prevented.

Marking criteria.

• 1 mark — Correctly explains the natural selection mechanism of resistance (pre-existing variants + selection pressure + survival and reproduction of resistant, producing a resistant-dominated population).
• 1 mark — Names at least two molecular mechanisms of resistance with correct named examples (e.g. beta-lactamase / MRSA PBP2a / efflux pumps / porin loss).
• 1 mark — Identifies at least two human behaviours that accelerate resistance (e.g. overprescribing for viral infections, stopping courses early, agricultural sub-therapeutic use) and links each to its mechanism (increase in selection pressure).
• 1 mark — Critically evaluates antibiotic stewardship as a management strategy: correct explanation of how it reduces selection pressure AND a genuine limitation (compliance, international coordination, patient pressure).
• 1 mark — Critically evaluates a second management strategy (e.g. completing courses, agricultural reform, new drug development, phage therapy) with both effectiveness and a limitation.
• 1 mark — Uses real data or named examples to support the argument (e.g. Australian MRSA data, vancomycin resistance timing, AMR death toll of 1.27 million).
• 1 mark — Explicitly distinguishes between "inevitable eventually" and "cannot be slowed" — the distinction between evolutionary inevitability and the rate of resistance emergence is critical to a Band 5–6 evaluative response.
• 1 mark — Reaches an explicit evaluative conclusion that rejects the claim's policy implication (resistance cannot be meaningfully slowed) with a justified reason that integrates the mechanisms, behaviours and strategies discussed.